NASDAQ:AFMD
Affimed N.V. Stock News
$5.42
+0.120 (+2.26%)
At Close: May 03, 2024
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
06:30am, Thursday, 15'th Apr 2021
Heidelberg, Germany, April 15, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported fin
Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announces pre-clin
Here's Why Shares of Affimed Skyrocketed Today
02:44pm, Friday, 09'th Apr 2021
A 100% response rate is impressive, albeit in just four patients.
Affimed Stock Price Increased Over 25% Pre-Market: Why It Happened
07:47am, Friday, 09'th Apr 2021
The stock price of Affimed NV (NASDAQ: AFMD) has increased by over 25% pre-market. This is why it happened.
Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity
07:04am, Friday, 09'th Apr 2021
Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cel
Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021
06:30am, Thursday, 08'th Apr 2021
Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today tha
Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced t
AFMD Stock Price Increased 23.77%: Why It Happened
11:20pm, Wednesday, 10'th Mar 2021
The stock price of Affimed NV (NASDAQ: AFMD) has increased by 23.77%. This is why it happened.
Affimed Announces Presentations at the AACR Annual Meeting 2021
05:22pm, Wednesday, 10'th Mar 2021
Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today th
Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data
08:26am, Wednesday, 10'th Mar 2021
Following the Independent Review Committee's assessment, Affimed NV (NASDAQ: AFMD) will continue enrollment in Phase 2 REDIRECT trial evaluating AFM13 as a monotherapy for relapsed or refractor
Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today i
Steven Cohen Ups the Ante on Affimed
12:15pm, Tuesday, 09'th Feb 2021
Steven Cohen (Trades, Portfolio), the billionaire investor who leads Point72 Asset Management, disclosed earlier this week his firm upped its stake in Affimed NV (NASDAQ:AFMD) by 190.73%.
Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors
06:30am, Wednesday, 03'rd Feb 2021
Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today
Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate abil
